Halo Pharma Nears Activation of $45M Sterile Injectable Line
- Halo Pharma is completing GMP qualification of a new sterile injectable manufacturing line backed by $45 million investment.
- The platform will deliver 50+ million units annually and support batch sizes from 250 to 250,000 units using Groninger UFVN FlexFill equipment.
- Expansion targets US-based pharma seeking domestic sterile manufacturing capacity; line expected online by year-end 2026.
Operational Impact
Halo Pharma's new sterile injectable line adds 50+ million annual units of domestic US capacity and relieves regional fill-finish bottlenecks for emerging biotech and large pharma seeking compliant contract manufacturing partners.
Source: PharmaSource RSS